Oragenics Inc (OGEN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Oragenics Inc (OGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012280
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oragenics Inc (Oragenics) is a biopharmaceutical company that focuses on the development and commercialization of novel antibiotics against infectious disease and develops treatments for oral mucositis. The company develops a new class of potent gram-positive antibiotics which are called Lantibiotics for combating resistant bacterial infections. Its pipeline products include MU1140, being tested for healthcare associated infections caused by drug-resistant bacteria. The company develops other candidates and technologies in the oral care and weight loss areas which include AG013 for the treatment of oral mucositis in cancer patients; OG716 in preclinical phase for healthcare-associated infections; and LPT3-04 for weight loss. Oragenics is headquartered in Tampa, Florida, the US.

Oragenics Inc (OGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Oragenics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Intrexon Enters into Co-Development Agreement with Oragenics 10
Oragenics Enters Into Co-Development Agreement With Intrexon 11
Licensing Agreements 13
Oragenics Amends Licensing Agreement with Texas A&M University System 13
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 15
Oragenics Enters Into Licensing Agreement With PharmaForce 17
Equity Offering 18
Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 18
Oragenics Raises USD6.7 Million in Private Placement of Shares 19
Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 20
Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 21
Oragenics Raises USD4.7 Million in Private Placement of Shares 22
Oragenics Completes Public Offering Of Shares For US$11 Million 24
Oragenics Completes Private Placement Of Shares For US$4 Million 25
Oragenics Completes Private Placement Of Common Stock For US$13 Million 26
Asset Transactions 27
Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 27
Oragenics Inc – Key Competitors 28
Oragenics Inc – Key Employees 29
Oragenics Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Apr 18, 2017: Oragenics Provides First Quarter 2017 Update 31
Corporate Communications 32
Jun 06, 2016: Oragenics Announces new President, Chief Executive Officer and Member of the Board of Directors 32
Product News 33
08/23/2016: Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections 33
Clinical Trials 34
May 02, 2016: Oragenics Announces Positive Results from Confirmatory Animal Study of AG013 for Treatment of Oral Mucositis and Plans to Finalize Phase 2 Clinical Trial Protocol 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Oragenics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oragenics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oragenics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oragenics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Oragenics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Intrexon Enters into Co-Development Agreement with Oragenics 10
Oragenics Enters Into Co-Development Agreement With Intrexon 11
Oragenics Amends Licensing Agreement with Texas A&M University System 13
Oragenics Enters Into Licensing Agreement With Intrexon For Lantibiotics 15
Oragenics Enters Into Licensing Agreement With PharmaForce 17
Oragenics Raises USD3.3 Million in Rights Offering of Preferred Shares 18
Oragenics Raises USD6.7 Million in Private Placement of Shares 19
Oragenics Raises USD1.7 Million in Second Tranche of Private Placement of Series A Preferred Stock 20
Oragenics Raises USD1.3 Million in First Tranche of Private Placement of Series A Preferred Stock 21
Oragenics Raises USD4.7 Million in Private Placement of Shares 22
Oragenics Completes Public Offering Of Shares For US$11 Million 24
Oragenics Completes Private Placement Of Shares For US$4 Million 25
Oragenics Completes Private Placement Of Common Stock For US$13 Million 26
Oragenics Sells Certain Probiotic Business Assets to ProBiora Health 27
Oragenics Inc, Key Competitors 28
Oragenics Inc, Key Employees 29
Oragenics Inc, Other Locations 30

★海外企業調査レポート[Oragenics Inc (OGEN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Virgin Australia Holdings Ltd:企業の戦略・SWOT・財務分析
    Virgin Australia Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Virgin Australia Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Ubisoft Entertainment SA (UBI):企業の財務・戦略的SWOT分析
    Ubisoft Entertainment SA (UBI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Northfork Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Northfork Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • L Brands Inc:戦略・SWOT・企業財務分析
    L Brands Inc - Strategy, SWOT and Corporate Finance Report Summary L Brands Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • United Services Automobile Association:企業の戦略・SWOT・財務情報
    United Services Automobile Association - Strategy, SWOT and Corporate Finance Report Summary United Services Automobile Association - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Truman Arnold Companies, Inc.:企業の戦略・SWOT・財務分析
    Truman Arnold Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Truman Arnold Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Malaysia Airlines Berhad:戦略・SWOT・企業財務分析
    Malaysia Airlines Berhad - Strategy, SWOT and Corporate Finance Report Summary Malaysia Airlines Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Crexendo Inc (CXDO):企業の財務・戦略的SWOT分析
    Summary Crexendo Inc (Crexendo) is a technology company that offers critical voice and data technology infrastructure services. The company offers internet phones, colour internet phones, SIP phone, DTA phones and mobile applications. It offers cloud communication and network services. Crexendo’s ne …
  • Shenzhen Neptunus Interlong Bio-Technique Co Ltd (8329):企業の財務・戦略的SWOT分析
    Summary Shenzhen Neptunus Interlong Bio-Technique Co Ltd (Neptunus) manufactures and distributes gene engineering drugs and preventive biological products. The company’s products include recombinant human interferon a-2b injection, used to treat hepatitis and cancers; recombinant human interleukin-2 …
  • Bristol-Myers Squibb Company:企業のM&A・事業提携・投資動向
    Bristol-Myers Squibb Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bristol-Myers Squibb Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Campbell Soup Company (CPB):企業の財務・戦略的SWOT分析
    Campbell Soup Company (CPB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • People’S Bank:企業の戦略・SWOT・財務分析
    People'S Bank - Strategy, SWOT and Corporate Finance Report Summary People'S Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Apexigen Inc-製薬・医療分野:企業M&A・提携分析
    Summary Apexigen Inc (Apexigen) is a clinical-stage biopharmaceutical company t hat focuses on discovery and development of antibody-based drugs for the treatment of cancer.The company’s lead immune oncology program APX005M, is a humanized monoclonal antibody that stimulates cancer specific T-cell r …
  • ProSiebenSat.1 Media SE (PSM):企業の財務・戦略的SWOT分析
    ProSiebenSat.1 Media SE (PSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Bridgford Foods Corporation:企業の戦略・SWOT・財務情報
    Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report Summary Bridgford Foods Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • PolyNovo Ltd (PNV)-製薬・医療分野:企業M&A・提携分析
    Summary PolyNovo Ltd (PolyNovo), formerly Calzada Limited is a medical device company that designs, develops and manufactures solutions for standalone and combination devices. The company offers products such as biodegradable temporizing matrix and negative pressure wound therapy dressing systems. I …
  • Starpharma Holdings Ltd (SPL):医療機器:M&Aディール及び事業提携情報
    Summary Starpharma Holdings Ltd (Starpharma) is a biotechnology company, which researches, develops and manufactures dendrimer products for pharmaceutical, life sciences and other applications. Dendrimers are synthetic nanoscale polymers with pharmaceutical and medical uses. The company’s developmen …
  • Jacobs Engineering Group Inc (JEC):電力:M&Aディール及び事業提携情報
    Summary Jacobs Engineering Group Inc (Jacobs) is a professional services company. It offers a diverse range of technical, professional, and construction services. The company's service portfolio includes project; process, scientific and specialty consulting; engineering and construction; and operati …
  • OSE Immunotherapeutics (OSE):製薬・医療:M&Aディール及び事業提携情報
    Summary OSE Immunotherapeutics (OSE), formerly OSE Pharma SA is a biotechnology company that discovers and develops immunotherapy products against invasive and metastatic late-stage cancers. The company’s memopi technology is employed in studying the development of treatments for ovarian, colon and …
  • Sumitomo Metal Mining Co Ltd:戦略・SWOT・企業財務分析
    Sumitomo Metal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Sumitomo Metal Mining Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆